Bottom line
What does VGHAX hold?
VGHAX held 97 positions as of Jul 31, 2026. Its largest holding is Eli Lilly & Co at 8.61% of the fund, and the top 10 positions add up to 40.6%. By asset type it is 98% stocks, 2% repurchase agreements, 0% cash & short-term funds.
Updated Sep 28, 2026
VGHAX top 25 holdings
| # | Holding | Type | % of fund | Value |
|---|---|---|---|---|
| 1 | Eli Lilly & Co ELI LILLY & CO |
Stocks | 8.61% | $3.3B |
| 2 | Merck & Co Inc MERCK & CO |
Stocks | 5.44% | $2.1B |
| 3 | Johnson & Johnson JOHNSON&JOHNSON |
Stocks | 4.83% | $1.8B |
| 4 | AstraZeneca PLC ASTRAZENECA PLC |
Stocks | 4.59% | $1.8B |
| 5 | UnitedHealth Group Inc UNITEDHEALTH GRP |
Stocks | 4.05% | $1.5B |
| 6 | Gsk Plc | Stocks | 3.00% | $1.1B |
| 7 | Edwards Lifesciences Corp EDWARDS LIFE |
Stocks | 2.56% | $977.6M |
| 8 | Intuitive Surgical Inc INTUITIVE SURGIC |
Stocks | 2.52% | $963.0M |
| 9 | CVS Health Corp CVS HEALTH CORP |
Stocks | 2.52% | $961.8M |
| 10 | Cencora Inc CENCORA INC |
Stocks | 2.47% | $944.6M |
| 11 | Vertex Pharmaceuticals Inc VERTEX PHARM |
Stocks | 2.36% | $901.8M |
| 12 | AbbVie Inc ABBVIE INC |
Stocks | 2.30% | $879.8M |
| 13 | Danaher Corp DANAHER CORP |
Stocks | 2.18% | $833.6M |
| 14 | Regeneron Pharmaceuticals Inc REGENERON PHARM |
Stocks | 2.14% | $817.7M |
| 15 | Novartis AG NOVARTIS AG-REG |
Stocks | 1.91% | $728.6M |
| 16 | Elevance Health Inc ELEVANCE HEALTH |
Stocks | 1.83% | $698.4M |
| 17 | Argenx SE ARGENX SE |
Stocks | 1.68% | $642.1M |
| 18 | HCA Healthcare Inc HCA HEALTHCARE I |
Stocks | 1.68% | $641.7M |
| 19 | Ucb Sa | Stocks | 1.67% | $637.1M |
| 20 | Boston Scientific Corp BOSTON SCIENTIFC |
Stocks | 1.53% | $582.9M |
| 21 | Agilent Technologies Inc AGILENT TECH INC |
Stocks | 1.49% | $570.1M |
| 22 | Biogen Inc BIOGEN INC |
Stocks | 1.46% | $557.2M |
| 23 | Galderma Group AG GALDERMA GROUP A |
Stocks | 1.37% | $524.5M |
| 24 | Roche Holding AG ROCHE HOLDING AG-GENUSSCHEIN - PART.CERTIFICATES |
Stocks | 1.18% | $450.1M |
| 25 | Dexcom Inc DEXCOM |
Stocks | 1.18% | $449.3M |
Source: SEC Form N-PORT, period ended Jul 31, 2026, filed Sep 28, 2026